Naslov
Pharmacoeconomic analysis in Alzheimer’s disease: What is the impact of diagnostic timing?

Autori
Vitezić, Dinko

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Neurologia Croatica / Šimić, Goran ; Mimica, Ninoslav - Zagreb, 2014, 54-54

Skup
Croatian Congress on Alzheimer's Disease (CROCAD-14)

Mjesto i datum
Brela, Hrvatska, 01.10.2014. - 04.10.2014

Vrsta sudjelovanja
Pozvano predavanje

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
Alzheimer’s disease; antidementive drugs; pharmacoeconomic analysis; cost-effectiveness

Sažetak
Pharmacoeconomic analysis which includes the cost-effectiveness of treatments for Alzheimer’s disease (AD) is an important issue from the economic and public health perspectives. In the most of European countries antidementive pharmacotherapy is accepted as cost effective according to specific guidelines for different patients groups (mild, moderate, and severe AD). In Croatia the most frequently used antidementive agent in 2013 was memantine (three times more then cholinesterase inhibitors, e.g. donepezil), which is certainly the result of earlier acceptance to National health insurance Drug list (HZZO Drug list), but could also be discussed as diagnosis of patients in later stages of disease. Today’s medical technology can enable the earlier detection of AD (mild cognitive impairment, pre dementia or incipient dementia), which could offer earlier therapeutic intervention. On the other hand, in practice, the majority of patients are not diagnosed in a timely manner. From the clinical as well as from the pharmacoeconomical point of view it is of great importance to determine to what extent the timing of diagnosis and specific therapeutic intervention affects its cost- effectiveness. There is a limited data and very few studies in this field, but according to some models it is shown that therapeutical timing is crucial in determining the economic benefits of a treatment. Better results with cost-effective therapy are directly connected with early diagnosis and AD drug therapy.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA